|
1
|
Carney DN and Hansen HH: Non-small-cell
lung cancer - stalemate or progress? N Engl J Med. 343:1261–1262.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanna N, Shepherd FA, Fossella FV, et al:
Randomized Phase III trial of pemetrexed versus docetaxel in
patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scagliotti G, Hanna N, Fossella F, et al:
The differential efficacy of pemetrexed according to NSCLC
histology: a review of two Phase III studies. Oncologist.
14:253–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
9
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shepherd FA, Dancey J, Ramlau R, et al:
Prospective randomized trial of docetaxel versus best supportive
care in patients with non-small-cell lung cancer previously treated
with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103.
2000.
|
|
11
|
Fossella FV, DeVore R, Kerr RN, et al:
Randomized phase III trial of docetaxel versus vinorelbine or
ifosfamide in patients with advanced non-small-cell lung cancer
previously treated with platinum-containing chemotherapy regimens.
The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol.
18:2354–2362. 2000.
|
|
12
|
Hayashi Y, Kuriyama H, Umezu H, et al:
Class III β-tubulin expression in tumor cells is correlated with
resistance to docetaxel in patients with completely resected
non-small-cell lung cancer. Intern Med. 48:203–208. 2009.
|
|
13
|
Wang LF, Yin HT, Qian XP, et al: β-Tubulin
III mRNA expression and docetaxel sensitivity in non-small cell
lung cancer. Clin Invest Med. 32:E2782009.
|
|
14
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jackman D, Pao W, Riely GJ, et al:
Clinical definition of acquired resistance to epidermal growth
factor receptor tyrosine kinase inhibitors in non-small-cell lung
cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Onoshi T, Watanabe K, Furuse K, et al:
Late phase II trial of RP56976 (docetaxel) in patients with
non-small-cell lung cancer. Gan To Kagaku Ryoho. 22:59–65.
1995.PubMed/NCBI
|
|
17
|
Yokoyama A, Kurita Y, Watanabe K, et al:
Early phase II clinical study of RP56976 (docetaxel) in patients
with primary pulmonary cancer: Docetaxel Cooperative Study Group
for Lung Cancer. Gan To Kagaku Ryoho. 21:2609–2616. 1994.PubMed/NCBI
|
|
18
|
Maruyama R, Nishiwaki Y, Tamura T, et al:
Phase III study, V-15-32, of gefitinib versus docetaxel in
previously treated Japanese patients with non-small-cell lung
cancer. J Clin Oncol. 26:4244–4252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee KH, Han SW, Hwang PG, et al: Epidermal
growth factor receptor mutations and response to chemotherapy in
patients with non-small-cell lung cancer. Jpn J Clin Oncol.
36:344–350. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hotta K, Kiura K, Toyooka S, et al:
Clinical significance of epidermal growth factor receptor gene
mutations on treatment outcome after first-line cytotoxic
chemotherapy in Japanese patients with non-small cell lung cancer.
J Thorac Oncol. 2:632–637. 2007. View Article : Google Scholar
|
|
21
|
Wu SG, Yang CH, Yu CJ, et al: Good
response to pemetrexed in patients of lung adenocarcinoma with
epidermal growth factor receptor (EGFR) mutations. Lung Cancer.
72:333–339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rudin CM, Avila-Tang E, Harris CC, et al:
Lung cancer in never smokers: molecular profiles and therapeutic
implications. Clin Cancer Res. 15:5646–5661. 2009. View Article : Google Scholar : PubMed/NCBI
|
